Dianthus Therapeutics, Inc.
DNTHNASDAQHealthcare● Active
$81.64
+$1.13(+1.40%)
Market Cap$3.4B
P/E Ratio—
52W High$96.5
52W Low$16.64
Dianthus Therapeutics, Inc. (DNTH) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DNTH · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.85
Est. -$1.17 · +27.4%
Revenue
$0.00B
Est. $0.00B · +14.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
DNTH reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.00B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.00B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.85 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 5, 2026 | -$1.17 | -$0.85 | +27.4% | $0.00B | $0.00B | +14.7% |
| ▼ Q1 FY2026 | Mar 9, 2026 | -$0.98 | -$1.43 | -45.9% | $0.00B | $0.00B | -48.6% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$0.86 | -$0.97 | -12.8% | $0.00B | $0.00B | -0.5% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.86 | -$0.88 | -2.3% | $0.00B | $0.00B | -77.7% |
| ▲ Q2 FY2025 | May 12, 2025 | -$0.86 | -$0.82 | +4.7% | $0.00B | $0.00B | +44.1% |
| ▲ Q1 FY2025 | Mar 11, 2025 | -$0.85 | -$0.81 | +4.7% | $0.00B | $0.00B | +38.8% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.59 | -$0.74 | -25.4% | $0.00B | $0.00B | +157.3% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.85
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
-$0.85
EPS Est.
-$1.17
EPS Surpr.
+27.4%
Revenue
$0.00B
Q1 FY2026
Mar 9, 2026Miss
EPS Actual
-$1.43
EPS Est.
-$0.98
EPS Surpr.
-45.9%
Revenue
$0.00B
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$0.97
EPS Est.
-$0.86
EPS Surpr.
-12.8%
Revenue
$0.00B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.88
EPS Est.
-$0.86
EPS Surpr.
-2.3%
Revenue
$0.00B
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$0.82
EPS Est.
-$0.86
EPS Surpr.
+4.7%
Revenue
$0.00B
Q1 FY2025
Mar 11, 2025Beat
EPS Actual
-$0.81
EPS Est.
-$0.85
EPS Surpr.
+4.7%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.74
EPS Est.
-$0.59
EPS Surpr.
-25.4%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 3 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 3 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 3 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 3 |
| Q4 FY2027 | $-1.35 | $-1.25 | $-1.21 | 2 |
| Q3 FY2027 | $-1.19 | $-1.10 | $-1.07 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 5 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +27.4% | $89.34 | $90.24 | +1.01% |
| ▼ Q1 FY2026 | Mar 9, 2026 | -45.9% | $65.20 | $79.23 | +21.52% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -12.8% | $33.20 | $33.73 | +1.60% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -2.3% | $20.39 | $19.15 | -6.08% |
| ▲ Q2 FY2025 | May 12, 2025 | +4.7% | $19.59 | $20.08 | +2.50% |
| ▲ Q1 FY2025 | Mar 11, 2025 | +4.7% | $24.34 | $23.38 | -3.94% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -25.4% | $29.41 | $29.90 | +1.67% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -2.0% | $25.80 | $26.74 | +3.64% |
Q2 FY2026+1.01%
Report Date
May 5, 2026
EPS Beat/Miss
+27.4%
Price Before
$89.34
Price After
$90.24
Q1 FY2026+21.52%
Report Date
Mar 9, 2026
EPS Beat/Miss
-45.9%
Price Before
$65.20
Price After
$79.23
Q4 FY2025+1.60%
Report Date
Nov 5, 2025
EPS Beat/Miss
-12.8%
Price Before
$33.20
Price After
$33.73
Q3 FY2025-6.08%
Report Date
Aug 7, 2025
EPS Beat/Miss
-2.3%
Price Before
$20.39
Price After
$19.15
Q2 FY2025+2.50%
Report Date
May 12, 2025
EPS Beat/Miss
+4.7%
Price Before
$19.59
Price After
$20.08
Q1 FY2025-3.94%
Report Date
Mar 11, 2025
EPS Beat/Miss
+4.7%
Price Before
$24.34
Price After
$23.38
Q4 FY2024+1.67%
Report Date
Nov 7, 2024
EPS Beat/Miss
-25.4%
Price Before
$29.41
Price After
$29.90
Q3 FY2024+3.64%
Report Date
Aug 8, 2024
EPS Beat/Miss
-2.0%
Price Before
$25.80
Price After
$26.74
Avg Beat Reaction-0.14%
Avg Miss Reaction+4.47%
Beat Rate3 / 8 quarters
Largest Move+21.52% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DNTH ends December
Dianthus Therapeutics, Inc. (DNTH) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.85 — beating the analyst consensus of $-1.17 by +27.4%. The next DNTH earnings date is expected around September 1, 2026.
Each quarter, investors track DNTH earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DNTH revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DNTH's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DNTH earnings · 5 questionsDianthus Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. DNTH typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DNTH historically reports after market close (AMC).
DNTH earnings datewhen is DNTH earningsDNTH next earnings datewhen does DNTH report earningsDNTH earnings calendar
▸ Source: FMP · Dianthus Therapeutics, Inc. SEC filings · US GAAP · Dianthus Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026